EP1660517A4 - Nogo receptor antagonists - Google Patents

Nogo receptor antagonists

Info

Publication number
EP1660517A4
EP1660517A4 EP04707073A EP04707073A EP1660517A4 EP 1660517 A4 EP1660517 A4 EP 1660517A4 EP 04707073 A EP04707073 A EP 04707073A EP 04707073 A EP04707073 A EP 04707073A EP 1660517 A4 EP1660517 A4 EP 1660517A4
Authority
EP
European Patent Office
Prior art keywords
nogo receptor
nogo
receptor antagonists
antigen
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04707073A
Other languages
German (de)
French (fr)
Other versions
EP1660517A2 (en
Inventor
Daniel H S Lee
R Blake Pepinsky
Weiwei Li
Sylvia A Rabacchi
Jane K Relton
Dane S Worley
Stephen M Strittmatter
Dinah W Y Sah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Biogen Inc
Biogen MA Inc
Original Assignee
Yale University
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/025004 external-priority patent/WO2004014311A2/en
Application filed by Yale University, Biogen Idec Inc, Biogen Idec MA Inc filed Critical Yale University
Publication of EP1660517A2 publication Critical patent/EP1660517A2/en
Publication of EP1660517A4 publication Critical patent/EP1660517A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)

Abstract

Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same.
EP04707073A 2003-08-07 2004-01-30 Nogo receptor antagonists Withdrawn EP1660517A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2003/025004 WO2004014311A2 (en) 2002-08-10 2003-08-07 Nogo receptor antagonists
PCT/US2004/002702 WO2005016955A2 (en) 2003-08-07 2004-01-30 Nogo receptor antagonists

Publications (2)

Publication Number Publication Date
EP1660517A2 EP1660517A2 (en) 2006-05-31
EP1660517A4 true EP1660517A4 (en) 2006-10-04

Family

ID=34192565

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04707073A Withdrawn EP1660517A4 (en) 2003-08-07 2004-01-30 Nogo receptor antagonists

Country Status (11)

Country Link
EP (1) EP1660517A4 (en)
JP (1) JP2007501612A (en)
CN (1) CN1926147A (en)
AU (1) AU2004264405A1 (en)
BR (1) BRPI0413426A (en)
CA (1) CA2535007A1 (en)
IS (1) IS8339A (en)
MX (1) MXPA06001444A (en)
NO (1) NO20061081L (en)
PL (1) PL380274A1 (en)
WO (1) WO2005016955A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
PL375301A1 (en) 2002-08-10 2005-11-28 Biogen Idec Ma Inc. Nogo receptor antagonists
ES2215469B1 (en) 2002-09-30 2005-12-16 Bsh Electrodomesticos España, S.A. AIR CONDITIONER.
ES2215470B1 (en) 2002-09-30 2005-12-16 Bsh Electrodomesticos España, S.A. AIR CONDITIONER.
NZ607886A (en) 2003-03-19 2014-09-26 Biogen Idec Inc Nogo receptor binding protein
BRPI0512500A (en) 2004-06-24 2008-03-11 Biogen Idec Inc treatment or conditions involving demyelination
JP5060293B2 (en) 2004-08-03 2012-10-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド TAJ in neural function
WO2006124627A2 (en) * 2005-05-12 2006-11-23 Biogen Idec Ma Inc. Methods of treating conditions involving neuronal degeneration
WO2007008732A2 (en) 2005-07-07 2007-01-18 Yale University Compositions and methods for suppressing axonal growth inhibition
PT1904104E (en) 2005-07-08 2013-11-21 Biogen Idec Inc Sp35 antibodies and uses thereof
EP1928905B1 (en) 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
WO2007089601A2 (en) 2006-01-27 2007-08-09 Biogen Idec Ma Inc. Nogo receptor antagonists
WO2008013782A2 (en) 2006-07-24 2008-01-31 Biogen Idec Ma Inc. Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of sp35 or trka antagonists
WO2008036858A2 (en) 2006-09-20 2008-03-27 The Board Of Regents Of The University Of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
CN105111310B (en) 2006-11-21 2019-07-26 雅培制药有限公司 The neutralizing monoclonal antibody and application thereof of anti-NOGO-66 receptor (NGR)
CN102014961B (en) 2008-01-22 2017-10-13 得克萨斯大学体系董事会 The volatile anesthetic composition containing extractant for local anaesthesia and/or pain relief
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CA2729961C (en) 2008-07-09 2018-05-01 Biogen Idec Ma Inc. Li113, li62 variant co2, anti-lingo antibodies
JP5951498B2 (en) 2009-12-08 2016-07-13 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー Monoclonal antibody against RGMA protein for use in the treatment of retinal nerve fiber layer degeneration
PE20142168A1 (en) 2012-01-27 2015-01-17 AbbVie Deutschland GmbH and Co KG COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH THE DEGENERATION OF NEURITES
NZ702178A (en) 2012-05-14 2017-01-27 Biogen Ma Inc Lingo-2 antagonists for treatment of conditions involving motor neurons
JP2018504400A (en) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． LINGO-1 antagonist and use for treatment of demyelinating disorders
CN110488007A (en) * 2019-09-26 2019-11-22 天津华科泰生物技术有限公司 A kind of immunochromatographydetection detection card and preparation method thereof of quick detection glial fibrillary acidic albumen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475753B1 (en) * 1998-06-16 2002-11-05 Human Genome Sciences, Inc. 94 Human Secreted Proteins
WO2003035687A1 (en) * 2001-10-22 2003-05-01 Novartis Ag Nogo receptor homologues and their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475753B1 (en) * 1998-06-16 2002-11-05 Human Genome Sciences, Inc. 94 Human Secreted Proteins
WO2003035687A1 (en) * 2001-10-22 2003-05-01 Novartis Ag Nogo receptor homologues and their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GRANDPRE T ET AL: "Nogo-66 receptor antagonist peptide promotes axonal regeneration", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 417, 30 May 2002 (2002-05-30), pages 547 - 551, XP002963387, ISSN: 0028-0836 *
See also references of WO2005016955A2 *

Also Published As

Publication number Publication date
CA2535007A1 (en) 2005-02-24
EP1660517A2 (en) 2006-05-31
NO20061081L (en) 2006-04-18
PL380274A1 (en) 2007-01-22
WO2005016955A3 (en) 2006-07-20
IS8339A (en) 2006-03-07
MXPA06001444A (en) 2006-05-15
CN1926147A (en) 2007-03-07
AU2004264405A1 (en) 2005-02-24
BRPI0413426A (en) 2006-10-17
WO2005016955A2 (en) 2005-02-24
JP2007501612A (en) 2007-02-01

Similar Documents

Publication Publication Date Title
IL173559A0 (en) Nogo receptor antagonists
IS8339A (en) Anti-NOGO receptor antagonists
WO2007089601A8 (en) Nogo receptor antagonists
HK1211618A1 (en) Nogo receptor binding protein nogo
WO2000018932A3 (en) Receptor based antagonists and methods of making and using
EP1572967A4 (en) Il-1 receptor based antagonists and methods of making and using
EA200600376A1 (en) ANTAGONISTS OF NOGO RECEPTOR

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060306

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SAH, DINAH, W.Y.

Inventor name: STRITTMATTER, STEPHEN, M.

Inventor name: WORLEY, DANE S.

Inventor name: RELTON, JANE K.

Inventor name: RABACCHI, SYLVIA A.

Inventor name: LI, WEIWEI355 BARD AVENUE APT. 1H

Inventor name: PEPINSKY, R. BLAKE

Inventor name: LEE, DANIEL H.S.

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

A4 Supplementary search report drawn up and despatched

Effective date: 20060905

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/47 20060101ALI20060830BHEP

Ipc: C07K 16/46 20060101ALI20060830BHEP

Ipc: C07K 7/08 20060101ALI20060830BHEP

Ipc: C07K 7/06 20060101ALI20060830BHEP

Ipc: C07K 1/00 20060101AFI20050301BHEP

17Q First examination report despatched

Effective date: 20061129

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1092479

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1092479

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130801